ALNY Latest Headlines

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Mon, 31-Aug 9:20 AM)

Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO-TTRansform Data

at www.tipranks.com (Mon, 31-Aug 9:05 AM)

Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential

at www.tipranks.com (Mon, 31-Aug 8:05 AM)

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)

at www.tipranks.com (Mon, 31-Aug 7:50 AM)

Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

at www.tipranks.com (Mon, 31-Aug 7:37 AM)

Stifel Nicolaus Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

at www.tipranks.com (Mon, 31-Aug 7:37 AM)

Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility

at www.tipranks.com (Mon, 31-Aug 5:32 AM)

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY)

at www.tipranks.com (Mon, 31-Aug 5:30 AM)

Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case

at seekingalpha.com (Sun, 30-Aug 12:43 PM)

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Amgen (AMGN)

at www.tipranks.com (Fri, 28-Aug 10:00 AM)

Alnylam drops as AstraZeneca posts full trial results for failed heart drug

at seekingalpha.com (Fri, 28-Aug 8:59 AM)

White House is said to announce drug pricing deals with biotechs

at seekingalpha.com (Wed, 26-Aug 12:40 PM)

Alnylam Cuts 2026 Guidance by $200 Million Amid Fraud Investigation—How Will Investors Respond?

Market Chameleon (Mon, 3-Aug 11:45 AM)

Alnylam Pharmaceuticals Delivers Record TTR Growth as Strategic Pipeline Advancements Signal Long-Term Value

Market Chameleon (Thu, 30-Jul 8:26 AM)